This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dion's Friday ETF Winners and Losers

Stocks in this article: VXX SLV CHIX

NEW YORK ( TheStreet) -- Welcome to Don Dion's Daily ETF Winners and Losers. Be sure to stop by each day to get a feel of who's winning and who's losing when it comes to ETFs.


iPath S&P 500 VIX Short Term Futures ETN (VXX) 8.9%

Yesterday's "flash crash" sent investors pouring into VIX-based exchange traded funds. Although the fund had been in a downward freefall for more than a year, Thursday and Friday's stumbling markets helped VXX recover nearly all of 2010's losses.

iShares Silver Trust (SLV) 3.9%

Despite a volatile Friday session, physically backed ETFs which track metals linked to industry are pocketing gains. Gold ETFs like the iShares Comex Gold Trust (GLD), on the other hand, were nearly unchanged at mid day trading.

Leading these metals higher is silver, which can be tracked using SLV or ETFS Physical Silver Shares (SIVR).

Global X China Financials ETF (CHIX) 3.4%

While the troubles facing Greece are commanding most of the headlines, there is another economic storm raging in China. Although CHIX is scoring gains today, the nation's banks have struggled recently as China's government attempts to rein in its overheating housing market.

China's markets should be volatile heading into the near future. If investors want to try their luck, I would advise them to avoid large-cap ETFs and opt instead for the Claymore/AlphaShares China Small Cap ETF (HAO).


iShares Nasdaq Biotechnology Index Fund (IBB) -3.5%

The biotech industry is taking a big hit today. Helping to lead IBB and other biotech ETFs lower during Friday's trading were Dendreon (DNDN) and ImmunoGen (IMGN). Just days ago DNDN rallied big on news that its cancer drug had received approval from the Food and Drug Administration.

The performance of DNDN over the past week highlights how volatile biotech stocks tend to be and how a stronger case can be made for owning an ETF in this space.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs